Home Nucleus Pharmaceuticals U.K. Lysosomal Storage Disorder Drugs Market to 2032

U.K. Lysosomal Storage Disorder Drugs Market to 2032

Overview

The U.K. Lysosomal Storage Disorder Drugs Market is expected to reach a 956.65 USD Million by 2032 and is projected to grow at a CAGR of 11.42% from 2025 to 2032.

Revenue, 2024 (USD Million)
448.72
Forecast, 2032 (USD Million)
956.65
CAGR, 2024 - 2032
11.42%
Report Coverage
U.K.

U.K. Lysosomal Storage Disorder Drugs Market 2018-2032 USD Million

U.K. Lysosomal Storage Disorder Drugs Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 448.72 USD Million
  • Projected Market Size (2032): 956.65 USD Million
  • CAGR (2025-2032): 11.42%

Key Findings of U.K. Lysosomal Storage Disorder Drugs Market

  • The U.K. Lysosomal Storage Disorder Drugs Market was valued at 448.72 USD Million in 2024.
  • The U.K. Lysosomal Storage Disorder Drugs Market is likely to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Hospital Pharmacies in Distribution Channel Segment accounted for the largest share of the market with a revenue of 306.17 USD Million
  • The fastest growing segment Imiglucerase in Drugs Segment grew Fastest with a CAGR of 14.41% during the forecast period from 2024 to 2032.

U.K. Lysosomal Storage Disorder Drugs Market Scope

U.K. Lysosomal Storage Disorder Drugs Market Segmentation & Scope
Route of Administration
  • Others
  • Oral
  • Subcutaneous (SC)
  • Intravenous (IV)
Age Group
  • Geriatric
  • Adults
  • Pediatric
Gender
  • Female
  • Male
Distribution Channel
  • Online Pharmacies
  • Drugs Stores and Retail Pharmacies
  • Hospital Pharmacies
Drugs
  • Others
  • Avalglucosidase Alfa
  • Galsulfase
  • Agalsidase Alpha
  • Laronidase
  • Taliglucerase Alfa
  • Velaglucerase
  • Alglucosidase Alpha
  • Idursulfase
  • Agalsidase Beta
  • Imiglucerase
Type of Disorder
  • Others
  • Krabbe Disease
  • Niemann-Pick Disease
  • Mucopolysaccharidosis (MPS)
  • Pompe Disease
  • Fabry Disease
  • Gaucher Disease
Type
  • Others
  • Chaperone Therapy
  • Substrate Reduction Therapy (SRT)
  • Enzyme Replacement Therapy (ERT)

U.K. Lysosomal Storage Disorder Drugs Market Data Coverage Insights

Study Period 2024-2032
Base Year 2023
Unit Revenue in USD Million
Market Value in 2024 448.72 USD Million
Market Value in 2032 956.65 USD Million
CAGR (2025-2032) 11.42%
Historic Data 2016-2023
Market Segments Covered Route of Administration,Age Group,Gender,Distribution Channel,Drugs,Type of Disorder,Type

Regional Insights:

  • Leading Market (2024-2032): U.K., leading in terms of revenue 448.72 USD Million in 2024
    • Key Country: U.K., leading in terms of revenue with value of 448.72 USD Million in 2024.

Segments and Scope

  • U.K. Lysosomal Storage Disorder Drugs Market to 2032, By Route of Administration
    • Intravenous (IV) is the largest segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 257.00 USD Million in the year 2024.
    • Subcutaneous (SC) is the Fastest growing segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 10.75 % in forecast period 2025-2032.
  • U.K. Lysosomal Storage Disorder Drugs Market to 2032, By Age Group
    • Pediatric is the largest segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 185.14 USD Million in the year 2024.
    • Pediatric is the Fastest growing segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 12.59 % in forecast period 2025-2032.
  • U.K. Lysosomal Storage Disorder Drugs Market to 2032, By Gender
    • Male is the largest segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 247.12 USD Million in the year 2024.
    • Male is the Fastest growing segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 12.31 % in forecast period 2025-2032.
  • U.K. Lysosomal Storage Disorder Drugs Market to 2032, By Distribution Channel
    • Hospital Pharmacies is the largest segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 306.17 USD Million in the year 2024.
    • Online Pharmacies is the Fastest growing segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.58 % in forecast period 2025-2032.
  • U.K. Lysosomal Storage Disorder Drugs Market to 2032, By Drugs
    • Imiglucerase is the largest segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 95.26 USD Million in the year 2024.
    • Imiglucerase is the Fastest growing segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 14.41 % in forecast period 2025-2032.
  • U.K. Lysosomal Storage Disorder Drugs Market to 2032, By Type of Disorder
    • Gaucher Disease is the largest segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 152.09 USD Million in the year 2024.
    • Gaucher Disease is the Fastest growing segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 12.51 % in forecast period 2025-2032.
  • U.K. Lysosomal Storage Disorder Drugs Market to 2032, By Type
    • Enzyme Replacement Therapy (ERT) is the largest segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a revenue of 289.87 USD Million in the year 2024.
    • Substrate Reduction Therapy (SRT) is the Fastest growing segment in U.K. Lysosomal Storage Disorder Drugs Market to 2032 with a Growth rate of 11.26 % in forecast period 2025-2032.

U.K. Lysosomal Storage Disorder Drugs Market Company Share Analysis

 
Company Name Company Share Analysis
Takeda Pharmaceutical Company Limited
Pfizer Inc.
Sanofi
BioMarin
Amicus Therapeutics, Inc.
U.K. Lysosomal Storage Disorder Drugs Market Company Share Analysis

U.K. Lysosomal Storage Disorder Drugs Market Geographical Sales Distribution, 2018-2032 USD Million

U.K. Lysosomal Storage Disorder Drugs Market Geographical Sales Distribution, 2018-2032 USD Million

U.K. Lysosomal Storage Disorder Drugs Market Company Profiling

U.K. Lysosomal Storage Disorder Drugs Market Company Profiling

Industry Related Reports

South America Cold Sore Treatment Market
Middle East & Africa Cold Sore Treatment Market
North America Cold Sore Treatment Market
Europe Cold Sore Treatment Market
Asia-Pacific Cold Sore Treatment Market
Argentina Cold Sore Treatment Market
Australia Cold Sore Treatment Market
Austria Cold Sore Treatment Market
Belgium Cold Sore Treatment Market
Brazil Cold Sore Treatment Market
Frequently Asked Questions
The U.K. Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Route of Administration,Age Group,Gender,Distribution Channel,Drugs,Type of Disorder,Type.
U.K. Lysosomal Storage Disorder Drugs Market was valued at USD 448.72(Revenue in USD Million) in 2023.
U.K. Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
The Hospital Pharmacies segment is expected to dominate the U.K. Lysosomal Storage Disorder Drugs Market, holding a largest market share of 306.17 USD Million in 2024

U.K. Lysosomal Storage Disorder Drugs Market Scope

U.K. Lysosomal Storage Disorder Drugs Market Segmentation & Scope
Route of Administration
  • Others
  • Oral
  • Subcutaneous (SC)
  • Intravenous (IV)
Age Group
  • Geriatric
  • Adults
  • Pediatric
Gender
  • Female
  • Male
Distribution Channel
  • Online Pharmacies
  • Drugs Stores and Retail Pharmacies
  • Hospital Pharmacies
Drugs
  • Others
  • Avalglucosidase Alfa
  • Galsulfase
  • Agalsidase Alpha
  • Laronidase
  • Taliglucerase Alfa
  • Velaglucerase
  • Alglucosidase Alpha
  • Idursulfase
  • Agalsidase Beta
  • Imiglucerase
Type of Disorder
  • Others
  • Krabbe Disease
  • Niemann-Pick Disease
  • Mucopolysaccharidosis (MPS)
  • Pompe Disease
  • Fabry Disease
  • Gaucher Disease
Type
  • Others
  • Chaperone Therapy
  • Substrate Reduction Therapy (SRT)
  • Enzyme Replacement Therapy (ERT)
Frequently Asked Questions
The U.K. Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Route of Administration,Age Group,Gender,Distribution Channel,Drugs,Type of Disorder,Type.
U.K. Lysosomal Storage Disorder Drugs Market was valued at USD 448.72(Revenue in USD Million) in 2023.
U.K. Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
The estimated market value of the U.K. Lysosomal Storage Disorder Drugs Market for final year is USD 956.65 (USD Million).

U.K. Lysosomal Storage Disorder Drugs Market Company Profiling

U.K. Lysosomal Storage Disorder Drugs Market Company Profiling
Frequently Asked Questions
The U.K. Lysosomal Storage Disorder Drugs Market is segmented based on Segmentation Route of Administration,Age Group,Gender,Distribution Channel,Drugs,Type of Disorder,Type.
U.K. Lysosomal Storage Disorder Drugs Market was valued at USD 448.72(Revenue in USD Million) in 2023.
U.K. Lysosomal Storage Disorder Drugs Market is projected to grow at a CAGR of 11.42% during the forecast period of 2024 to 2032.
The estimated market value of the U.K. Lysosomal Storage Disorder Drugs Market for final year is USD 956.65 (USD Million).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.

BROWSE RELATED PAGES